Published 03 April 2018 | By Novo Nordisk Pharmatech A/S
The vaccine industry is challenged to produce large quantities of vaccines in a rapid and cost-effective way. Major changes to current bioprocesses are both difficult and very expensive to implement.
For more information, click here
